Heterogeneous estimates of influenza virus types A and B in the elderly: Results of a meta-regression analysis by Panatto, Donatella et al.
Influenza Other Respi Viruses. 2018;1–11.	 	 	 | 	1wileyonlinelibrary.com/journal/irv
1  | INTRODUC TION
Like that of many other infectious diseases, the epidemiology of in-
fluenza displays several age- dependent features. First of all, influ-
enza attack rates are generally higher in children than in adults and, 
especially, the elderly. For instance, a meta- regression analysis by 
Jayasundara et al1 has shown that the natural attack rate is about 
four times higher (15.2% vs 3.5%) in children than in adults. Our 
previous research2 documented that, in ten consecutive seasons, 
children aged 0- 14 years had the highest cumulative incidence of 
influenza- like illness (ILI), followed by 15- to 64- year- olds, while the 
lowest cumulative incidence was constantly reported in the elderly. 
On the other hand, despite the lower incidence rates, influenza- 
attributable hospitalizations and mortality are highest among the 
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Influenza has many age- dependent characteristics. A previous systematic review of 
randomized controlled trials showed that the detection rate of influenza B was higher 
in children than in non- elderly adults. However, no comprehensive reviews have tar-
geted the elderly, who carry the main burden of disease. We aimed to quantify the 
relative detection rates of virus types A and B among the elderly, to identify factors 
affecting these proportions, and to compare type distribution among seniors and 
younger age- classes. A comprehensive literature search was conducted to identify 
multiseason studies reporting A and B virus type distributions in the elderly. A 
random- effects meta- analysis was planned to quantify the prevalence of type B 
among elderly subjects with laboratory- confirmed influenza. Meta- regression was 
then applied to explain the sources of heterogeneity. Across 27 estimates identified, 
the type B detection rate among seniors varied from 5% to 37%. Meta- analysis was 
not feasible owing to high heterogeneity (I2 = 98.5%). Meta- regression analysis 
showed that study characteristics, such as number of seasons included, hemisphere, 
and setting, could have contributed to the heterogeneity observed. The final ad-
justed model showed that studies that included both outpatients and inpatients re-
ported a significantly (P = .024) lower proportion than those involving outpatients 
only. The detection rate of type B among the elderly was generally lower than in 
children/adolescents, but not non- elderly adults. Influenza virus type B has a rela-
tively low detection rate in older adults, especially in settings covering both inpa-
tients and outpatients. Public health implications are discussed.
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elderly; on average, about 90% of influenza- related deaths occur in 
people aged 65 years or older.3-5
The magnitude of incidence is not the only age- related attribute 
of epidemic curves; the relative timing of the onset and peak of an 
epidemic is also likely to differ among age- groups. Although it is as 
yet unclear who exactly “drives” epidemics (eg, both pre- school and 
school children6,7 and high- school students8 have been implicated), 
it seems that younger populations are more likely to spread the virus 
in their households. However, the relative timing of seasonal epi-
demics also depends on the circulating (sub)type.9
Available virological data1 also support the above- mentioned 
thesis concerning the age dependency of influenza, in that different 
influenza (sub)types affect different age- classes in different ways. 
Let us remember that there are three “classic” influenza virus types: 
A, B, and C. Of these, influenza virus types A (IVA) and B (IVB) are 
of major public health interest. On the basis of two major surface 
glycoproteins, namely hemagglutinin (H) and neuraminidase (N), IVA 
is further divided into subtypes; A (H1N1) and A (H3N2) have been 
clearly dominant for several years. IVB, by contrast, has evolved into 
two distinct lineages, Victoria and Yamagata.10-12 Moreover, a fourth 
type of influenza virus, dubbed “D”, has recently been proposed, 
whose role in humans is uncertain.13,14 The meta- regression analysis 
cited above1 highlighted the fact that IVB has a relatively greater im-
pact on children than on adults, the ratio IVB/IVA being 0.45 in chil-
dren and 0.25 in adults. These estimates are of importance to public 
health planning and policies. For instance, owing to the lack of data 
on vaccine efficacy/effectiveness (VE) in the various age- classes, the 
relative advantage of the recently introduced quadrivalent influenza 
vaccine (QIV) (which contains both IVB lineages) over trivalent (TIV) 
formulations has usually been calculated mathematically15-17 from 
a set of epidemiological parameters. These have included, for ex-
ample, the mean relative detection rate (DR) of IVB, the mean level 
of lineage mismatch between the IVB included in TIV and that in 
circulation, and a meta- analytically obtained level of cross- lineage 
protection provided by TIV. It is, however, evident that, while the DR 
of IVB in children is about twice as high as that seen in adults, the 
relative advantage of QIV over TIV would be significantly greater 
among younger populations. Moreover, a somewhat age- dependent 
cost- effectiveness profile of QIV has recently been demonstrated 
in the United Kingdom (UK):18 QIV would be cost- effective in chil-
dren with an increased cost of up to £6.36 per dose; if, however, the 
program was extended to at- risk individuals aged <65 years and fur-
ther to all elderly subjects, the maximum incremental cost per dose 
would be £1.84 and £0.20, respectively.
This study had three objectives, two of which were co- primary 
and one secondary. The co- primary objectives were (1a) to quantify 
the proportions of IVA and IVB in relation to the total number of vi-
ruses detected (IVA+IVB) among the elderly, and (1b) to identify fac-
tors influencing the relative prevalence of influenza virus types. The 
secondary objective was to compare the distribution of IVA and IVB 
among the elderly with that observed among younger age- classes.
Considering the previous findings,1 we hypothesized an uneven 
distribution of IVA and IVB among different age- classes, whereby 
the impact of IVB was relatively greater in younger people. This 
study is of importance for all relevant stakeholders for at least two 
reasons. First, the previously published meta- regression1 considered 
only randomized controlled trials (RCTs) and therefore did not in-
clude nationally or regionally representative influenza surveillance 
data. Although RCTs allow both prospective monitoring of influenza 
attack rates and more rigorous bias control, they are usually con-
ducted with the aim of comparing two or more different strategies, 
in a limited time- frame and with a limited number of participants; 
thus, they may not fully reflect the “real- world” scenario. Population- 
based surveillance studies may at least partially address these is-
sues.19 Moreover, the analysis by Jayasundara et al1 was not able 
to establish IVA/IVB attack rates among the elderly, owing to the 
paucity of studies and missing information. Other recently published 
reviews on the epidemiology and burden of IVB have considered, 
for instance, single countries20 or have not aimed to analyze IVA/
IVB distribution patterns from the perspective of age.21 Second, no 
comprehensive reviews on the impact of IVA/IVB in the elderly are 
available; elderly people are the primary target of annual influenza 
vaccination in all industrialized and many developing countries. Given 
the variety of influenza vaccines available for immunization (such as 
trivalent and quadrivalent, adjuvanted and non- adjuvanted),22 in-
sights from this epidemiological review could be helpful in future 
pharmacoeconomic and health technology assessment (HTA) evalu-
ations aimed at establishing an equitable vaccination policy.
2  | METHODS
2.1 | Compliance with international standards
We followed the “Methodological guidance for systematic reviews 
of observational epidemiological studies reporting prevalence 
and cumulative incidence data” proposed by researchers from the 
Joanna Briggs Institute.23 The meta- analyses of observational stud-
ies in epidemiology (MOOSE) checklist24 were also consulted.
2.2 | Study endpoints, population, and key 
definitions
In accordance with the above- described study objectives, the study 
endpoints were as follows:
1a. Proportion of IVB to the total number of viruses detected 
(IVA+IVB) in the elderly;
1b. Factors associated (see below) with the relative frequency of IVB 
in the elderly;
2. Relative risk (RR) of detecting IVB in the elderly as compared with 
younger age-classes.
We defined “elderly subjects” according to the two most widely 
used	cutoffs	of	≥60	and	≥65	years.25
Laboratory- confirmed influenza cases were defined as cases 
that tested positive in diagnostic assays described by Vemula et al26 
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including mainly viral cultures and reverse transcriptase polymerase 
chain reaction (PCR).
Given both the different timing of influenza epidemics in the 
Southern and Northern Hemispheres and the fact that several stud-
ies may not have reported the exact surveillance period, the defi-
nition of an influenza season took into account the study location, 
and was adapted from Caini et al.27 For example, the study period of 
“2012- 14” refers to the three consecutive seasons (2012- 13, 2013- 
14, and 2014- 15) in the Northern Hemisphere or to the three con-
secutive years (2012, 2013, and 2014) in the Southern Hemisphere.
2.3 | Search strategy
A comprehensive literature search was conducted; this included 
both automatic and manual modalities. As the authors of this study 
were aware that several studies27-31 on the outcomes of interest 
were available, the automatic search strategy was constructed in 
several steps until all known studies appeared among the search 
results. To do this, it was first assumed that studies reporting the 
frequency of IVB would also report that of IVA. Even if this were not 
the case, the frequency of IVA could have easily been imputed by 
subtracting IBV isolates from the total number of isolates. Studies 
that quantified IVB were sought using a combination of both MeSH 
(medical subject headings) terms and text words. The search strings 
regarding the study population, that is the elderly, were adapted 
from Jefferson et al32 The algorithm was developed by two investi-
gators (AS and DP) and approved by the whole team. The search was 
limited to the period of “1990- Current.” No other filters were ap-
plied. The search strategy was first implemented in Medline via Ovid 
(Box S1) and then adapted to Embase. The search was performed on 
June 26, 2017.
Subsequently, we automatically searched the so- called gray 
literature; this search was conducted at greylit.org. Given the lim-
ited number of available records, the only search term used was 
“influenza.”
The automatic search was completed by the manual search; this 
was done by means of the standard citation- tracking method of the 
studies included.
2.4 | Study selection process
After the removal of duplicates, the results of each automatic search 
were pooled into a single spreadsheet, and a first screening was per-
formed to eliminate clearly irrelevant titles. The remaining set of pa-
pers underwent abstract screening. In these first two steps, articles 
were removed if they: (i) did not refer to laboratory- confirmed influ-
enza or (ii) had a clearly different study population (ie, <60 years). 
Subsequently, full texts of potentially eligible papers were assessed; 
to be included in the review, these had to meet all of the following 
inclusion criteria:
1. Separate	 data	 on	 IVA	 and	 IVB	 among	 people	 aged	 ≥60/65;
2. Coverage of at least five consecutive influenza seasons;
3. Total number of infections detected (IVA+IVB) among the elderly 
>100.
Seroepidemiological surveys were excluded.33
During the selection process, we realized that some studies had 
been conducted by the same research groups, and that the same 
databases had been used to answer different research questions. In 
such cases, we selected the study with the highest number of vi-
ruses detected and/or covering the most seasons.
2.5 | Data extraction and abstraction
The data were extracted and inserted into a spreadsheet by DP; this 
procedure was then cross- checked by DA. The following parameters 
were extracted: first author, year of publication, country/location, 
study setting/surveillance system, study period, virus detection and 
characterization laboratory methods, age- classes for which data of 
interest were reported, total, and by- type age- class- specific abso-
lute number of influenza viruses detected.
When data were not readily available for extraction, the au-
thors of papers (i) reporting results only through percentages/
charts, but without a clearly stated denominator or (ii) indicat-
ing an age stratification in the “Methods” but not reporting age- 
specific data in the “Results” were contacted by email for further 
details.
Any instances of mixed infections (IVA + IVB) or type C infec-
tions were excluded from the total count. Although some were de-
tected, these, however, accounted for a negligible proportion.
Some studies reported relative frequencies of IVA and IVB on a 
scale that was different (eg, % distribution of IVB among different 
age- classes) from the study endpoints (ie, % distribution of IVA and 
IVB in a given age- class). However, as these studies also reported the 
total number of IVA and IVB, the absolute numbers of interest in a 
given age- class was easily recalculated.
Age categorization was performed once the study selection 
process had been deemed completed. In a few studies that further 
broke down the elderly population into categories, these estimates 
were	 summed	 to	 form	a	 single	 age	 category	of	≥60/65	years.	The	
main challenge lay in classifying the pediatric population; indeed, 
most studies reported data of interest separately for age- groups of 
0- 4/5 and 4/5- 14/17/18 years, while some combined the two latter 
groups into a single category. We therefore used the following classi-
fication: “young children” (0- 4/5 years), “older children/adolescents” 
(4/5- 14/17/18 years), “children/adolescents” (0- 14/17/18 years), 
“adults”	(14/17/18/25-	60/64	years),	and	“elderly”	(≥60/65	years).
2.6 | Study variables
The following variables were considered in the analysis:
1. Number of influenza seasons;
2. A dichotomous variable indicating the hemisphere;
3. Absolute centroid latitude of study location;
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4. A dichotomous variable indicating whether the 2009 pandemic 
fell within the study period;
5. A categorical variable with three levels indicating the study set-
ting [outpatients only, inpatients/severe acute respiratory infec-
tion (SARI) only, both outpatients and inpatients/SARI].
2.7 | Quality assessment
Following consultation of the World Health Organization’s 
(WHO) manual “Global Epidemiological Surveillance Standard for 
Influenza,”34 we realized that some of our endpoints and inclusion 
criteria could be regarded as quality attributes. Indeed, we consid-
ered only laboratory- confirmed influenza, studies with clear virus 
type and age- class distributions, a sufficient period of time [to avoid 
short- period studies driven by a single (sub)type] and number of vi-
ruses detected among the study population. This could be described 
as the “minimum criteria for inclusion” approach.23 A formal critical 
appraisal was, however, conducted by means of a 9- item tool created 
by researchers from the Joanna Briggs Institute.23
However, a difficulty emerged regarding the representative-
ness of the study population (item 1 of the appraisal tool). Indeed, 
representativeness is a multifaceted issue. It may be sentinel or 
non- sentinel, inpatient or outpatient, cover a geographically rep-
resentative area or not, etc.35 The distribution of swabs taken 
from patients of different ages often does not reflect the age- 
structure of the general population; indeed, the probability of 
being tested for influenza differs significantly among single age- 
classes.36 Regarding the surveillance system, it was deemed that 
the estimates included were representative within the context of 
their setting and spatial coverage. The study setting was, however, 
considered a priori to be a potential confounder (see above). By 
contrast, with regard to age- class- specific representativeness, we 
realized that this was only partly addressed by including studies 
with at least 100 positive tests among the elderly. We therefore 
compared the proportion of positive tests from the elderly with 
the percent of the elderly population, as reported by the World 
Bank (mean annual proportion of the study period).37 The age- 
adjusted proportion of positive tests from the elderly was then 
used in meta- regression as a potential predictor of the study’s pri-
mary endpoint.
2.8 | Statistical analysis
Spearman’s ρ coefficient was used to measure correlation between 
the number of viruses detected from the elderly and the weight 
of the elderly in the general population, as per World Bank.37 
Subsequently, a simple linear model was constructed in order to ad-
just the proportion of positive tests from the elderly to the percent 
of the elderly population in a given country.
Given that we expected a high level of heterogeneity among 
single studies,1 and in line with explicit recommendations from 
Munn et al23 on the pooling of prevalence estimates, all models 
were planned a priori to be random- effects. Heterogeneity was 
quantified by both I2 and Q test. In particular, we expected to pool 
the proportion of IVB with the total number of viruses detected 
(IVA+IVB) in the elderly (endpoint 1a) and express this outcome 
as a raw proportion (by applying the arcsine square- root trans-
formation). However, no pooled result was retained in the case of 
I2 > 85%.38
We decided a priori to carry out two types of sensitivity analysis. 
The first would involve the sequential omission of estimates from 
single studies. In the second, we would omit studies that could po-
tentially include overlapping participants, that is, studies conducted 
in the same territory and/or covering overlapping influenza seasons. 
Thus, only studies with the largest number of estimates from a given 
study location would be retained. Publication bias was planned to be 
checked by means of both the visual inspection of funnel plots and 
Egger’s test.
To explain the heterogeneity observed and/or find factors asso-
ciated with endpoint 1a, a set of univariable meta- regressions (end-
point 1b) was carried out; the potential predictors were described 
earlier in the text. Independent variables deemed significant (P < .05) 
on univariable analysis were then included in a multivariable model, 
in which all P - values were adjusted for multiple testing.
The RR was used as a measure for our secondary endpoint, 
that is, to compare the IVB DR between the elderly and younger 
age- classes.
All analyses were conducted in Stata version 14 (StataCorp 
LP, College Station, TX, USA) and MetaXL version 5.1 (Epigear 
International).
3  | RESULTS
3.1 | Characteristics of studies included
The automatic search produced a total of 6733 unique records. 
Following duplicate removal (N = 946) and the screening of titles 
and abstracts (N = 5787), a total of 43 records were deemed to 
be worthy of further evaluation and the corresponding full texts 
were assessed. Of these, 16 papers27-31,39-49 met all inclusion cri-
teria and were included. In the study by Caini et al27 only 12 of 26 
study	 locations	 had	 a	 sufficient	 number	 (≥100)	 of	 isolates	 among	
the elderly. Moreover, we identified three potentially eligible papers 
by Mosnier et al31,43,50 that used the same database and almost the 
same time- frame. However, the number of reported isolates varied. 
Specifically, one paper31 dealt exclusively with the elderly, while 
other two43,50 also reported data of interest regarding younger age- 
classes. We therefore proceeded in the following way. As the first 
paper31 reported the largest number of viruses detected among the 
elderly, this study was included to address endpoints 1a and 1b. 
For endpoint 2, however, we selected one of the other two stud-
ies,43 as it presented a higher number of positive tests in the whole 
population. In any case, the relative estimates reported in these 
three studies were close to one another. The manual search did not 
produce results. An additional source of data51 was suggested by 
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a peer- reviewer. In sum, a total of 17 papers corresponding to 27 
IVB prevalence estimates were included in both the qualitative and 
quantitative assessments. The whole process of data selection is de-
picted in Figure S1.
The pre- specified characteristics of the studies included are 
reported in Table 1. Most (23/27) prevalence estimates were from 
the Northern Hemisphere and covered 19 different countries. All 
included studies were published/extracted within a relatively short 
period of time (2013- 2017). The median number of seasons covered 
was 8 [interquartile range (IQR): 6- 12] and most (22/27) prevalence 
estimates included the 2009 pandemic. The setting of most (15/27) 
estimates was from both outpatient and inpatient/SARI surveillance. 
The median number of IVA+IVB among the elderly was 737 (IQR: 
198- 2303).
All studies were judged to be of good quality in all domains, ex-
cept for checklist item 1 regarding representativeness. Indeed, on 
median, only 6.2% (IQR: 3.3%- 13.8%) of infections detected were 
from the elderly population, and the correlation between the num-
ber of positive tests from the elderly and the weight of the elderly 
in the general population was low (Spearman’s ρ = 0.45), although 
statistically significant (P = .020). Age adjustment of the proportion 
of IVA + IVB from the elderly enabled us to significantly increase the 
representativeness of the data.
3.2 | Detection rate of influenza type B in the 
elderly and its possible determinants
There was a 7- fold difference in estimates of IVB prevalence among 
the elderly, which ranged from 5.1% to 37.4% (Figure 1). The level of 
heterogeneity was very high (I2 = 98.5%; Q = 1752.7, P < .001), which 
did not allow us to obtain a pooled estimate.
To highlight possible sources of the heterogeneity observed, a 
set of univariable meta- regressions was performed (Table 2). Three 
predictors were found to be statistically associated with the relative 
DR of IVB among seniors. First, the IVB DR was significantly higher 
(P = .045) in the Northern Hemisphere than in the Southern. Second, 
studies that involved only outpatients were significantly (P < .001) 
more likely to report higher IVB DRs than those comprising both in- 
and outpatient surveillance systems. Third, studies covering a wider 
time- frame were more likely (P = .028) to report lower IVB DRs. 
These single models explained 11% to 32% of variance. As per peer- 
reviewer suggestion, we performed a post hoc meta- regression with 
the predictor of unadjusted (to the population structure) percent of 
IVB among the elderly in relation to the number of viruses detected 
in the whole population; no statistically significant (P = .25) associa-
tion emerged.
In the multivariable model, which included only significant vari-
ables determined at the previous step, the only statistically sig-
nificant predictor was “Setting” (P = .024 for “outpatient only” vs 
“in- and outpatient” surveillance systems; P = .42 “inpatient only” vs 
“outpatient only” surveillance systems). By contrast, the variables 
“Hemisphere” (P = .32) and “Number of seasons” (P = .25) did not 
prove to be significantly associated with the outcome.F
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3.3 | Detection rate of influenza type B in the 
elderly: comparison with younger age- classes
Table 3 compares IVB DRs among the elderly and younger age- 
classes in terms of RRs (elderly vs younger populations). In 80% 
(20/25) of studies, IVB DRs were lower among the elderly than 
among younger children. Direct comparison of elderly vs older chil-
dren/adolescents revealed that 92% (22/24) of studies had a RR<1; 
the effect sizes were generally higher than in the previous compari-
son “elderly vs younger children.” A similar pattern was observed 
when the two above- mentioned pediatric age- classes were com-
bined together. By contrast, the head- to- head comparison of elderly 
and non- elderly adults produced somewhat controversial findings: 
Higher and lower IVB DRs in the elderly were almost evenly distrib-
uted among single studies.
None of the above- reported pairwise comparisons were poolable 
owing to the very high heterogeneity (I2 > 94%; Q > 198, P < .001).
4  | DISCUSSION
The present study established the average multiseason proportions 
of IVA and IVB among the elderly in different settings and geograph-
ical areas; IVA was by far prevalent, while IVB accounted for less 
than a quarter of cases in most settings. We then demonstrated that 
the type- specific DRs among the elderly may depend on study char-
acteristics, such as the type of surveillance system. Finally, the DR of 
IVB among seniors tended to be substantially lower than in children 
and adolescents, but not non- elderly adults.
To the best of our knowledge, our study provides the first com-
prehensive review of the IVB proportion among the elderly. It may 
therefore be seen as a valuable addition to the previously cited meta- 
regression study of RCTs on the natural attack rate of IVA and IVB.1 
Indeed, that study did not quantify the natural attack rate of IVA/
IVB in the elderly, as two of the only three studies identified did not 
report data of interest, while the third reported a natural attack rate 
F IGURE  1 Detection rates of influenza 
types A and B among the elderly, by study
Variable Level Estimate (95% CI) P R2, %
Latitude – −0.0008	(−0.0032,	0.0016) .50 0
Hemisphere Northern Ref – 10.7
Southern −0.0919	(−0.1817,	−0.0021) .045
Setting Outpatient only Ref – 31.9
Inpatient only −0.0457	(−0.1370,	0.0456) .33
Inpatient and 
outpatient/SARI
−0.1147	(−0.1806,	−0.0488) <.001
Pandemic period 
included
No Ref – 0
Yes 0.0277	(−0.0617,	0.1171) .54
Number of seasons – −0.094	(−0.0178,	−0.0010) .028 12.6
Weighted % isolates 
among the elderly
– −0.0069	(−0.0150,	0.0011) .088 6.4
TABLE  2 Univariable meta- regression 
models to predict influenza type B 
detection rate among the elderly
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of zero. The paucity of studies identified is not surprising; indeed, 
randomized placebo- controlled trials have been very uncommon (at 
least in recent years) in this population group for purely ethical rea-
sons, in that annual influenza vaccination is recommended for the 
elderly.52 This is why epidemiological and surveillance evidence is 
of importance.53
However, a substantial difference in IVA/IVB DRs, which deter-
mined a very high heterogeneity, was reported by single studies. 
This fact did not allow us to retain any pooled estimate. The meta- 
regression approach helped us to identify possible confounders that 
may have been responsible for the heterogeneity observed in DR 
estimates. In the final adjusted model, we ascertained that the study 
setting/surveillance system may have contributed significantly to 
the heterogeneity observed. Specifically, the regression coeffi-
cients for “outpatients only” were lower than those for “inpatients 
only” and “in- and outpatients”, although only the latter reached an 
α < .05. The observed non- significance between “outpatients only” 
and “inpatients only” could be attributed to the relatively low num-
ber of studies involving the latter category.
The observed gap between study settings is probably attribut-
able to several factors. Although recent research has suggested that 
several clinical features and outcomes of IVA and IVB are similar,54,55 
it is largely unknown the relative frequency of hospitalization in 
IVA and IVB patients of different ages.56 Indeed, the frequency of 
hospitalization due to IVA/IVB may not reflect the epidemiological 
picture of circulating (sub)types. For instance, in the United States 
during the season 2007/2008, IVB was detected more frequently 
at population level, while the number of IVB hospitalized patients 
was about the half of IVA hospitalized patients.54 Other factors that 
may explain the difference observed are representativeness and 
Location [Ref]
Elderly vs 
children
Elderly vs 
adolescents
Elderly vs 
children/
adolescents Elderly vs adults
Hong Kong39 0.65 0.33 0.48 0.67
Vietnam40 NA NA 0.94 1.18
Finland41 0.70 0.31 0.44 0.42
Australia27 0.91 0.66 0.73 1.04
Chile27 0.71 0.31 0.47 0.94
China (North)27 0.66 0.77 0.73 0.95
China (South)27 0.89 0.93 0.92 1.05
El Salvador27 0.89 1.51 1.16 1.79
England27 0.95 0.66 0.71 0.87
Guatemala27 0.91 0.88 0.90 2.27
Italy27 0.81 0.27 0.37 0.83
New Zealand27 0.57 0.36 0.43 0.70
Nicaragua27 0.42 0.39 0.40 2.92
Singapore27 0.96 0.64 0.66 0.96
Vietnam27 1.00 0.82 0.91 1.16
Canada 
(Manitoba)42
0.51 0.26 0.39 0.43
France43 1.29 0.90 1.03 1.35
Hong Kong44 0.58 0.45 0.52 1.05
Hong Kong45 0.80 0.48 0.61 1.01
China (Shanghai)46 0.91 0.77 0.81 0.98
Egypt47 1.29 1.05 1.14 1.28
China 
(Chongqing)48
0.74 0.48 0.55 1.17
Germany28 1.17 0.59 0.71 0.94
Spain (Madrid)29 1.11 0.49 0.83 1.25
Canada 
(Toronto)49
NA NA 0.96 1.38
Australia30 0.93 0.59 0.68 0.95
United States51 0.86 NA 0.67* 0.91
*The age category is 5- 24 y; it therefore also includes young adults.
TABLE  3 Relative risk of influenza type 
B detection among the elderly in 
comparison with younger age- classes
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data quality. The outpatient ILI surveillance system may be more 
nationally representative, while inpatient/SARI surveillance may 
provide more in- depth and higher- quality data.57 As it has been sug-
gested57,58 that both surveillance types are of merit and should be 
regarded as complementary, we believe that the estimates of IVA/
IVB DRs from studies including both out- and inpatients better re-
flect reality.
Results regarding our secondary outcome confirmed the 
widely held thesis59 that IVB mainly affects young populations. 
Indeed, we found that young children and older children/adoles-
cents usually had a higher probability of IVB detection than the 
elderly, while no evident pattern could be observed between el-
derly and non- elderly adults. These results may be explained by 
the gradual exposure to IVB during the first two decades of life;60 
indeed, virtually all elderly subjects have been exposed to IVB 
during their lives.61 However, the question of cross- lineage IVB 
protection remains controversial: some studies have found consid-
erable cross- protection,62,63 while others64,65 have reported lim-
ited or no cross- protection. The most recent, and one of the most 
comprehensive, meta- studies was conducted by Beyer et al61 and 
may shed light on this issue. These authors found that mismatch 
of the IVB lineage (that included in TIV) impacted heavily on VE 
in young individuals (31.8%- 73.3%) but not in the elderly (2.4%- 
3.4%). However, why individuals aged 4/5- 14/17/18 (and not 
0- 4/5) years are major IVB spreaders remains largely unknown; 
future research into this is warranted.
Our results may have public health policy implications. For in-
stance, in the elderly, the age- class in which traditional influenza 
vaccines are often poorly immunogenic owing to immunosenes-
cence32,66 and IVB causes a relatively low burden, the implemen-
tation of enhanced vaccine formulations, such as MF59- adjuvanted 
TIV or high- dose TIV, may have significant advantages. Indeed, these 
vaccines have been shown to be more immunogenic and effective 
in the senior population.38,67-71 By contrast, QIVs may offer a sub-
stantial benefit in children and adolescents (especially those aged 
5- 17 years) owing to the significant presence of IVB in this age- class 
and the relatively high level of mismatch between the dominantly 
circulating IVB lineage and that included in TIVs. From our personal 
experience, we have learned that all available influenza vaccines dif-
fer in several aspects, and that each one is more appropriate for a 
given population group, a notion that is also exemplified by a recent 
paper by Bonanni et al72 on the appropriateness of different influ-
enza vaccines available in Italy. Indeed, some Italian regions have 
been implementing “age/risk- group” vaccine differentiation.73 This 
differentiation could also be attractive from the economic point of 
view; indeed, it has been estimated74 that a strategy in which MF59- 
adjuvanted TIV is used exclusively in the elderly, while QIV is used 
in younger age- groups, is the most cost- effective from the payer 
perspective.
This review is not without limitations. First, although we per-
formed a comprehensive literature search, we acknowledge that 
some relevant data might not have been found or not have been 
publicly available. Ideally, our search strategy should have involved 
common search engines, to locate appropriate national, regional or 
local information sources that are not indexed in the normally used 
scientific databases. However, the low specificity of the common 
search engines and the impossibility of constructing a comprehen-
sive search tree (which would involve hundreds of ad hoc queries in 
different languages) did not allow us to proceed in this way. We tried 
to limit this shortcoming by searching the “gray literature”, although 
this proved fruitless. In any case, we believe that both age- and (sub)
type- specific data should be routinely reported by the surveillance 
systems.
Second, our results come from a global perspective and should 
be regarded as average multiseason estimates. It is evident that, 
during seasons with an overall predominance of IVB, the DRs of 
IVB will be higher among the elderly. However, it has been demon-
strated (data from 12 European countries)75 that in the 2012/2013 
season, when IVB was clearly dominant, the elderly had a signifi-
cantly lower risk of IVB detection than 5- to 14- year- olds (RR 0.67, 
P < .001).
Third, the meta- analytic estimates were subject to very high het-
erogeneity and were therefore not retained. It should, however, be 
pointed out that, from our personal experience, meta- analytic prev-
alence estimates are very often associated with very high heteroge-
neity. Indeed, in the meta- analysis conducted by Jayasundara et al1,2 
values were constantly >90%. There are several ways of dealing with 
heterogeneity, including: (i) choosing a fixed- effects or a random- 
effects model; (ii) changing the statistical metric; (iii) excluding stud-
ies; (iv) omitting meta- analyses and conducting subgroup analysis or 
meta- regression.76 Here, we chose a more conservative approach; 
we omitted pooled results and carried out a set of meta- regressions 
to explain the heterogeneity observed. If, on the other hand, we had 
reported the pooled estimates relative to our endpoint 1a (IVB DR 
among the elderly), these would have been 14.0% (95% CI: 13.8%- 
14.1%) and 17.8% (95% CI: 15.8%- 19.8%) in the fixed- and random- 
effects models, respectively (results not shown).
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